Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.46 |
| ▸ | FAP | Q12884 | 1/20 | 0.46 |
| ▸ | CTSC | P53634 | 1/20 | 0.39 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27179974 | 1.00 | DPP4 (0.46) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL11347414 | 0.84 | DPP4 (0.47) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL7139196 | 0.84 | DPP4 (0.47) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL11347411 | 0.84 | DPP4 (0.47) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL4638730 | 0.82 | DPP4 (0.46) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL27601749 | 0.82 | DPP4 (0.46) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL6558952 | 0.82 | DPP4 (0.46) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL27300656 | 0.81 | DPP4 (0.44) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL515720 | 0.79 | SLC7A5 (0.41) | ENPEPSLC7A5 | |
| SCHEMBL515719 | 0.79 | SLC7A5 (0.41) | ENPEPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1548450-A | Glycyl valyl cysteinyl methionine | 尤伟昶 | 2004-11-24 | — | — | CN | claimed |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
| US-20040248868-A1 | Phophylactic and therapeutic use of hydroxysteroids | HUNTER-FLEMING LIMITED (GB) | 2004-12-09 | — | — | US | disclosed |
| CN-1548450-A | Glycyl valyl cysteinyl methionine | 尤伟昶 | 2004-11-24 | — | — | CN | disclosed |
| CN-1548451-A | Seryl seryl threony aspartic acid | 尤伟昶 | 2004-11-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248868-A1 | Phophylactic and therapeutic use of hydroxysteroids | CYP27A1, CYP27B1, HSD3B1 | DPP4 1337/4885DPP8 1471/4885DPP9 1338/4885 |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | DPP4 525/4885DPP8 644/4885DPP9 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.